News Releases Year None2022202120202019 Date Title Additional Formats March 14, 2022 Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis March 1, 2022 Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress February 9, 2022 Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD) Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 13 of 13
